SCHEMBL5166948

SCHEMBL5166948

COc1ccc([N+](=O)[O-])cc1-c1ccc(C=C2NC(=O)N(c3ccccc3)C2=O)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.54
ALDH1A1 P00352 8/20 0.54
MEN1 O00255 8/20 0.54
KMT2A Q03164 8/20 0.54
POLB P06746 7/20 0.54
KDM4E B2RXH2 6/20 0.54
TDP1 Q9NUW8 5/20 0.54
RECQL P46063 4/20 0.54
APEX1 P27695 2/20 0.54
CTDSP1 Q9GZU7 2/20 0.54
HPGD P15428 2/20 0.54
PSMD14 O00487 1/20 0.54
MMP2 P08253 1/20 0.54
DNMT1 P26358 1/20 0.54
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
F5 P12259 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5166946 1.00 MAPT (0.54) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL31358742 0.78 KMT2A (0.49) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL6389037 0.74 ALDH1A1 (0.57) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL6389034 0.74 ALDH1A1 (0.57) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL5144989 0.73 MAPT (0.70) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL5145006 0.73 MAPT (0.70) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL31358842 0.73 MEN1 (0.49) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL11968680 0.72 HTRA2 (0.68) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL6397410 0.71 TDP1 (1.00) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL6397407 0.71 TDP1 (1.00) MAPTALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005081642-A2 OPTICAL FILM, OPTICAL COMPENSATION SHEET, POLARIZNG PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE FUJI PHOTO FILM CO., LTD. (JP) 2005-09-09 WO disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MAPT 2096/4885ALDH1A1 2413/4885MEN1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.